{"entity":{"id":"nct06797986","kind":"trial","name":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","aka":[],"tldr":"A phase 1/2 trial of BVAC-E6E7 (low level) in head and neck squamous cell carcinoma, run by Cellid Co., Ltd., now recruiting.","summary":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. is a phase 1/2 interventional study registered as NCT06797986 by Cellid Co., Ltd., with 37 participants planned, started 2026-02-04 and due to reach its primary completion in 2027-03. Interventions recorded: BVAC-E6E7 (low level), BVAC-E6E7 (high level) and BVAC-E6E7 (RP2D).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06797986","url":"https://clinicaltrials.gov/study/NCT06797986"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06797986","phase":"1/2","setting":"A Phase I/IIa Clinical Trial to Investigate the Safety, Immunogenicity and Efficacy of BVAC-E6E7 in Subjects With HPV Type 16 and/or 18 Positive Unresectable Recurrent or Metastatic Head","sponsor":"Cellid Co., Ltd.","enrolled":37,"outcomes":[]},"route":"/trials/nct06797986/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}]}}